构建功能优化的全人源 B7-H3 CAR T 细胞以增强实体瘤治疗
Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.
临床上最先进的B7-H3 CAR源自鼠单克隆抗体(mAb) 376.96和MGA271,目前正在进行1/2期试验。
FRONTIER PAPERS
Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.
临床上最先进的B7-H3 CAR源自鼠单克隆抗体(mAb) 376.96和MGA271,目前正在进行1/2期试验。
Application of CAR-T therapy in solid tumors: current opportunities and challenges.
近年来,CAR-T 细胞疗法在治疗血液系统恶性肿瘤方面取得了实质性进展。
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。
CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.
CAR-T 细胞(CAR T细胞)对血液系统恶性肿瘤有效。
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法,CAR-T细胞疗法仍处于快速发展阶段。CAR-T细胞相关领域在未来仍将是研究热点。
Organoid-Immune Co-Cultures: A Next-Generation approach to disease modeling.
将类器官与免疫细胞结合在共培养系统中,标志着癌症研究和免疫学领域的突破性进展。
Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy.
B7-H3 是一种在许多实体瘤中过表达的细胞表面蛋白,也是嵌合抗原受体(CAR)T 细胞治疗一个有吸引力的靶点。
Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review.
靶向癌症治疗作用于靶向分子,对正常细胞的毒性较小,对癌细胞的作用更具特异性。
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。